RESMED, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 206.3 USD | -1.44% |
|
-3.25% | +19.95% |
ETFs positioned on ResMed, Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.03% | 1,006 M€ | -.--% | - | |
| 0.03% | 414 M€ | +10.84% | - | |
| 0.02% | 29 M€ | -.--% | - | |
| 0.02% | 322 M€ | +13.88% | - | |
| 0.02% | 17 M€ | +4.00% | - | |
| 0.02% | 9 M€ | +9.86% | - | |
| 0.02% | 17 M€ | +2.42% | - | |
| 0.02% | 105 M€ | +2.97% | - | |
| 0.02% | 1 M€ | +3.03% | - | |
| 0.02% | 26 M€ | +16.85% | - | |
| 0.02% | 32 M€ | +0.28% | - | |
| 0.02% | 7 M€ | +0.11% | - | |
| 0.02% | 6 M€ | +3.89% | ||
| 0.01% | 34 M€ | +3.86% | - | |
| 0.01% | 12 M€ | +15.06% | - | |
| 0.01% | 2 M€ | +3.16% | - | |
| 0.01% | 756 M€ | +0.05% | - | |
| 0.01% | 8 M€ | +0.25% | - | |
| 0.01% | 54 M€ | +0.47% | - |
ResMed, Inc. specializes in designing, manufacturing and marketing respiratory disorders diagnosis, treatments and management (primarily sleep respiratory disorders). Net sales break down by family of products as follows:
- medical devices (50.4%);
- masks (37.9%);
- software as a service (11.7%).
At the end of June 2021, the group had 6 production sites located in the United States (2), Australia, China, Singapore and Malaysia.
The United States accounts for 61.4% of net sales.
Calendar
31/07/2024
- Q4 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
206.3
USD
Average target price
216.6
USD
Spread / Average Target
+5.00%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +19.95% | 30.31B | |
| +7.01% | 217B | |
| +11.01% | 190B | |
| +19.20% | 143B | |
| +30.79% | 111B | |
| +1.48% | 64.59B | |
| +13.95% | 52.36B | |
| -0.16% | 48.45B | |
| -6.20% | 38.03B | |
| +0.91% | 35.6B |
- Stock Market
- Equities
- RMD Stock
- Funds and ETFs ResMed, Inc.
